We are live on ! Find out more
EIDX

Eidos Therapeutics, Inc. Common Stock
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

Back to rankings

79 hedge funds and large institutions have $411M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

1% more funds holding

Funds holding: 78 → 79 (+1)

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

2% less capital invested

Capital invested by funds: $418M → $411M (-$6.75M)

36% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 28

Holders
79
Holders Change
+1
Holders Change %
+1.28%
% of All Funds
1.73%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
17
Increased
18
Reduced
28
Closed
16
Calls
$112K
Puts
–
Net Calls
+$112K
Net Calls Change
+$112K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.06M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6.5M
3
Victory Capital Management
Victory Capital Management
Texas
+$6.18M
4
OAC
OMERS Administration Corp
Ontario, Canada
+$5.55M
5
PHS
PFM Health Sciences
California
+$4.93M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$27.4M
2
CS
Candriam SCA
Luxembourg
-$4.06M
3
PC
Polar Capital
United Kingdom
-$3.42M
4
Bank of America
Bank of America
North Carolina
-$2.08M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$2.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$2.08M +$636K +16,280 +39%
Charles Schwab
27
Charles Schwab
California
$1.56M -$154K -3,944 -8%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.55M -$845K -21,629 -33%
EGI
29
EAM Global Investors
California
$1.53M +$71.5K +1,831 +5%
SG Americas Securities
30
SG Americas Securities
New York
$1.45M +$1.42M +36,335 +903%
Goldman Sachs
31
Goldman Sachs
New York
$1.32M +$700K +17,929 +96%
EI
32
EAM Investors
California
$1.18M -$1.51M -38,548 -54%
Barclays
33
Barclays
United Kingdom
$1.15M +$176K +4,510 +16%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$852K – – –
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$827K +$899K +23,003 New
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$803K +$872K +22,331 New
WC
37
Wexford Capital
Florida
$719K -$391K -10,000 -33%
Squarepoint
38
Squarepoint
New York
$678K +$736K +18,855 New
CS
39
Credit Suisse
Switzerland
$651K +$707K +18,109 New
Federated Hermes
40
Federated Hermes
Pennsylvania
$643K +$590K +15,093 +542%
AllianceBernstein
41
AllianceBernstein
Tennessee
$626K -$62.5K -1,600 -8%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$620K +$8.05K +206 +1%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$599K -$2.93K -75 -0.4%
D.E. Shaw & Co
44
D.E. Shaw & Co
New York
$585K +$635K +16,255 New
HF
45
HRT Financial
New York
$577K +$627K +16,047 New
Morgan Stanley
46
Morgan Stanley
New York
$532K +$570K +14,589 +6,484%
Swiss National Bank
47
Swiss National Bank
Switzerland
$493K – – –
Bank of America
48
Bank of America
North Carolina
$453K -$2.08M -53,308 -81%
SO
49
STRS Ohio
Ohio
$420K – – –
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$410K – – –
1
2
3 4

EIDX Hedge Fund Activity: Q3 2019 in Review

79 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q3 2019, worth a combined $411M — down 1.6% from $418M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EIDX positions and 16 closed out — a net gain of 1 holder — while 18 added to existing stakes and 28 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $8.06M. The largest seller was Viking Global Investors, exiting entirely with an estimated $27.4M sold.

  • 79 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q3 2019, up from 78 in Q2 2019.
  • Funds reported $411M of Eidos Therapeutics, Inc. Common Stock stock for Q3 2019, down 1.6% quarter-over-quarter.
  • 17 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q3 2019 and 16 closed out, a net change of +1 holder.
  • The largest Eidos Therapeutics, Inc. Common Stock buyer in Q3 2019 was Fidelity Investments, an estimated $8.06M added.
  • The largest Eidos Therapeutics, Inc. Common Stock seller in Q3 2019 was Viking Global Investors, an estimated $27.4M sold.

Based on aggregated 13F filings for Q3 2019.